➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Colorcon
Dow
Medtronic
Moodys

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,835,492

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,835,492 protect, and when does it expire?

Patent 10,835,492 protects VYXEOS and is included in one NDA.

This patent has thirty-six patent family members in twenty-one countries.

Summary for Patent: 10,835,492
Title:Method of lyophilizing liposomes
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Inventor(s): Cabral-Lilly; Donna (Pennington, NJ), Mayer; Lawrence (North Vancouver, CA), Tardi; Paul (Surrey, CA), Watkins; David (East Greenwich, RI), Zeng; Yi (Somerset, NJ)
Assignee: CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:16/181,203
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Recent additions to Drugs Protected by US Patent 10,835,492

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER 209401 Aug 3, 2017 RX Yes   Get Started for $10   Get Started for $10 U-2341 METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER 209401 Aug 3, 2017 RX Yes   Get Started for $10   Get Started for $10 U-3150
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 10,835,492

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401-001 Aug 3, 2017 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,835,492

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012326370   Get Started for $10
Brazil 112014009305   Get Started for $10
Canada 2852777   Get Started for $10
China 104114156   Get Started for $10
China 108853031   Get Started for $10
Denmark 2768484   Get Started for $10
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.